Health Care

BioNTech’s Phase‑2 results for Trastuzumab Pamirtecan show a 47.9 % ORR and 8‑month PFS in HER2‑positive endometrial cancer, surpassing chemo and boosting stock outlook.

Intuitive Surgical’s Q1 2026 earnings may spark a turnaround as the company targets a growing robotic‑surgery market, focusing on sales velocity, repeat orders, and service revenue.

Tonix’s new sublingual TONMYA® shows superior PK and FDA approval, targeting fibromyalgia sleep‑related symptoms and positioning the company as a CNS innovation leader.

Explore Chemomab Therapeutics, a Tel Aviv‑based biotech tackling fibrosis‑related diseases with innovative therapies and a volatile yet promising stock trajectory.

AbbVie’s stock faces a bearish trend, but strong dividends, a 10% sales growth, and a $650 M partnership with RemeGen hint at resilience – can investors ride the dip or risk a slide?

Moderna’s share price surged 100% in six months, driven by promising mRNA‑4359 data and a robust pipeline of cancer, influenza, and RSV vaccines.

Pfizer’s post‑COVID pivot: investing billions in oncology and obesity while juggling FDA scrutiny, dividend stability, and a $150B market opportunity.

Tenaya Therapeutics’ 2025 annual report reveals shareholder votes on directors, auditor, and equity plan amid heart‑disease biotech volatility.

Evaxion Biotech’s AI‑Immunology platform hits 86% precision in a Phase II cancer‑vaccine trial and identifies ERV antigens in glioblastoma, showing scalable, next‑gen personalized oncology solutions.

Explore Zai Lab’s 2026 AGM details: director re‑elections, auditor appointments, shareholder resolutions, and its biopharma growth strategy.